NCIC CLINICAL TRIALS GROUP – GI DISEASE SITE COMMITTEE

PANCREAS
DISEASE ORIENTED GROUP

AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, EATON CHELSEA HOTEL, TORONTO

DATE SATURDAY, MAY 3rd, 2014

TIME: 11:00 – 11:45

CHAIRS: DR. STEVE GALLINGER, DR. DANIEL RENOUF

11:00  WELCOME AND INTRODUCTION/MEMBERSHIP UPDATE
       DR. S. GALLINGER/DR. D. RENOUF

11:05 – 11:20  OPEN TRIALS

GUEST PRESENTATION

PA.6 (ACCORD 24): RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA  

                  PROF. T. CONROY

11:20 – 11:30  TRIALS/CONCEPTS IN DEVELOPMENT

ALLIANCE 021101: NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE_ARM PILOT STUDY  

                  DR. A. WEI/DR. S. GALLINGER

11:30 – 11:37  INTERGROUP TASK FORCE UPDATE  

                  DR. S. GALLINGER

11:37 – 11:45  FOLFIRINOX REGISTRY UPDATE  

                  DR. J. MAROUN

11:45  CLOSING REMARKS